Differentiation of normal course and warning signs in puerperium, timing of follow-up, mental health and cardiometabolic screening, choice of contraceptive method in breastfeeding women.
⚕️ Target audience: This clinical review is intended for physicians and healthcare professionals; It is a summary of current literature and guidelines for educational purposes. Clinical decisions should be made based on patient-specific evaluation and applicable institutional protocols.
The postpartum period — the puerperium or "fourth trimester" — covers the weeks when pregnancy-related physiological changes return to the pre-pregnancy state. There is agreement on its beginning (birth of the newborn); The end is less clear and is considered the sixth to eighth week for most systems. However, not all organ systems return to baseline during this period, and the return does not progress linearly over time; ACOG therefore extends postpartum care to 12 weeks after birth and calls these 12 weeks the fourth trimester (ACOG Committee Opinion 736, 2018).
The traditional model consisted of a single check-up four to six weeks after birth. This model is abandoned for two reasons. First, timing: ovulation can return as early as 25 days after birth in a non-breastfeeding woman, and in some series up to 51% of pregnant women return to sexual activity before the sixth week visit (Jackson and Glasier 2011, Obstet Gynecol)—so leaving the contraception decision until the sixth week is too late. Second, the risk window: de novo severe maternal morbidity develops in 0.3-0.4% of patients after discharge, and this accounts for approximately 15% of all severe maternal morbidity (UpToDate, postpartum complications, December 2025). Moreover, attendance at the sixth week visit is far from complete: studies report rates ranging from 65-90% (Sonalkar 2018, Obstet Gynecol).
| Institution | First contact | Subsequent follow-up |
|---|---|---|
| ACOG (2018) | One contact (in person or by phone) to address acute issues within the first 3 weeks | Appropriate ongoing care and comprehensive postpartum visit at week 12 at the latest |
| WHO | on day 3 | Routine assessment at 1–2 weeks and at 6 weeks. |
| American Heart Association | High-risk day 7–10 visit (e.g., blood pressure check) | First well-being visit at 2–3 weeks (outpatient or telemedicine), comprehensive visit at 6 weeks, followed by maternal screening at the 2-, 6-, and 12-month pediatric visits |
| If hypertensive disease (ACOG) | Blood pressure measurement within 72 hours after discharge if there is severe hypertension during pregnancy/postpartum | In non-severe hypertension, 7-10 days at the latest. day |
Early visit (1-2 weeks) should be considered especially in the following groups: those who gave birth by cesarean section, those who have medical problems requiring close monitoring, those who have risk factors for postpartum depression (previous episode of depression, family history of mood disorders, concurrent stressful life events), and those who are at risk of PTSD after traumatic birth. In order to increase participation, it may be useful to explain the importance of the visit during the antenatal period, to make the appointment before discharge, and to remind (ACOG CO 736, 2018).
Knowing the limits of normal is a prerequisite for distinguishing pathology. A significant portion of patients report that they have difficulty distinguishing normal postpartum symptoms from complications.
Uterine involution. Immediately after delivery of the placenta, the fundus is hard, nontender, globular, and in the midline, a few centimeters below the umbilicus; It rises to the level of the umbilicus in the next 12 hours, then retreats ~1 cm per day, and by the end of the first week, it descends again between the symphysis pubis and the umbilicus. It is not abdominally palpable in two weeks, and reaches its pre-pregnancy size in six to eight weeks; uterine weight decreases from ~1000 g to 60 g. There is no evidence that uterine size predicts complications (UpToDate, postpartum physiology, July 2026).
Echogenic material on ultrasound is not a cause for panic: In a prospective study in which serial ultrasound was performed on postpartum days 1, 3, 7, 14, 28 and 56, the cavity was mostly empty in the early puerperium (day 1 and 3), fluid and debris were seen throughout the cavity in the middle puerperium (day 14), and the cavity was thin in the late puerperium (day 28 and 56). It emptied again as a white line. Intrauterine echogenic material is common in the first 48 hours after vaginal delivery and is not associated with the amount or duration of bleeding. This finding does not change the management of the patient who does not have heavy bleeding or signs of infection; On the other hand, in the presence of fever and/or bleeding, the echogenic mass may represent the residual pregnancy product (UpToDate, postpartum physiology, July 2026).
Lochia. In the first days, it becomes red/red-brown (lochia rubra), then pinkish-brown (lochia serosa; two to three weeks), and finally yellowish-white (lochia alba). The total volume is 200-500 mL and the average duration is one month; Up to 15% of women still experience lochia at the routine visit at six to eight weeks, and this duration does not appear to be related to lactation or contraceptive use. The most common cause of foul-smelling lochia without fever and abdominal pain is a forgotten sponge after an episiotomy or laceration repair (UpToDate, postpartum complications, December 2025).
Cervix, vagina, abdominal wall. The cervix remains dilated by 2-3 cm for the first few days and decreases to less than 1 cm in the first week; The external os never regains its pre-pregnancy shape—the small circular opening of the nulligravida becomes a wide, transverse, stellate slit. The abdominal wall regains most of its tone within a few weeks, but rectus diastasis may be permanent. The relatively hypoestrogenic state postpartum leads to vaginal dryness, which is more common in breastfeeding women: in a meta-analysis, the symptom of vaginal atrophy was more than twice as common in breastfeeding women (RR 2.34; 95% CI 1.65-3.32) (Perelmuter 2025, Obstet Gynecol).
Weight, cardiovascular and haematological. An average of 6 kg is lost with the outflow of the fetus, placenta and amniotic fluid, and another 2-7 kg is lost with uterine contraction and fluid loss during the puerperium; Approximately half of the weight gained during pregnancy is lost in the first six weeks. Cardiac output and stroke volume increase by ~60% and ~70%, respectively, in the first 10 minutes after term vaginal birth and gradually decline until the 24th postpartum week. Hematological changes return to baseline in 6-12 weeks; The critical point is that the prothrombotic state takes weeks to resolve, thus leaving the puerperal at risk for thromboembolic disease (UpToDate, postpartum physiology, July 2026).
Return of ovulation. Gonadotropins and sex steroids remain low in the first two to three weeks. In a non-breastfeeding woman, the average timing of the first menstruation is day 45–64, and that of the first ovulation is day 45–94; However, ovulation can occur as early as the 25th day. 70% of women menstruate by the 12th postpartum week, and 20–71% of first menstruations are preceded by ovulation—so the first cycle is potentially fertile (Jackson and Glasier 2011, Obstet Gynecol). Approximately 40% of fully breastfeeding women are still amenorrheic at six months (UpToDate, postpartum physiology, July 2026).
A significant proportion of postpartum complications arise after discharge; patient education is therefore an integral part of clinical follow-up. Clearly explain which symptoms require medical attention: bleeding that soaks a pad within one hour; signs of sepsis (fever, chills, tachycardia, dizziness/syncope, cold, clammy, pale skin, shortness of breath, altered consciousness); new or worsening perineal/uterine pain; dysuria; breast problems; shortness of breath, chest pain, leg pain or swelling; and significant mood disturbance that affects daily activities. Severe pain anywhere—especially in the head, chest, or abdomen—is a warning sign in its own right (ACOG CO 736, 2018).
| Table | Clinical tip |
|---|---|
| Preeclampsia / eclampsia | Hypertension and/or seizure may have postpartum onset; Most, but not all, cases in the first 48 hours. Severe hypertension (SBP ≥160 and/or DBP ≥110 mmHg) is always treated; The standard medication for seizure prevention and preventing recurrence is magnesium sulfate. Even the patient who remains normotensive during pregnancy is warned of the possibility of late postpartum preeclampsia |
| Bleeding | Bleeding that is greater than expected, producing signs/symptoms of hypovolemia. Diagnosis may be delayed due to intra-abdominal bleeding after vaginal birth or cesarean section, as bleeding is not observed after the abdomen is closed. If bleeding is not seen when there is tachycardia and hypotension, occult bleeding is considered. |
| Pulmonary embolism | Sudden onset dyspnea, pleuritic pain, haemoptysis. The most common findings in 38 patients with confirmed pulmonary embolism during pregnancy were dyspnea (62%), pleuritic chest pain (55%), cough (24%) and sweating (18%) (UpToDate, postpartum complications, December 2025) |
| Peripartum cardiomyopathy | Dyspnea, cough, orthopnea, paroxysmal nocturnal dyspnea, pedal edema. Diagnosis is delayed because weakness, shortness of breath and foot edema overlap with normal pregnancy; risk factors are older age, multiparity and black race (UpToDate, postpartum complications, December 2025) |
| Uterine inversion | A rare but urgent complication of the involuting uterus; severe hemorrhage and shock if not recognized and treated |
| Necrotizing fasciitis / group A streptococcus | Worsening vulvar edema + induration + perineal pain + marked leukocytosis (>20,000) with left shift; High fever and an identifiable cause are not always found. Early empiric antibiotics covering group A streptococcus; Surgical debridement is mandatory |
Postpartum hypertension has been reported as new onset in 0.3-7.5% of women (UpToDate, postpartum physiology, July 2026); Causes include intrapartum/postpartum volume overload, medications (e.g. ergot derivatives), pregnancy-related hypertension and underlying diseases. What is critical is the time window: in patients with antepartum/intrapartum preeclampsia, blood pressure typically falls within 48 hours but may rise again on days 3–6. Since hypertension may occur after discharge and be asymptomatic, ACOG recommends daily measurements for the first 72 hours and repeat measurement on days 7–10; If possible, the patient measures once or twice a day at home for the first two to three weeks (ACOG CO 736, 2018).
Venous thromboembolism is a leading cause of direct maternal death in high-income countries. The risk is higher in the postpartum than in the antepartum period and is more common after cesarean section; The period when it is highest is the first few weeks and gradually decreases to the baseline until the 12th week. In a systematic review, the risk of postpartum VTE was found to be up to five times higher than during pregnancy itself, and a 21-84 fold increase compared to baseline was reported in the first six weeks. The incidence rate is 357.3 in the first week, falls to 31.5 by week 6, and plateaus at 3.2 during weeks 7–12—a curve that is also the rationale for combined hormonal contraceptive timing discussed below (Jackson 2011, Obstet Gynecol—postpartum VTE review).
Healing time varies markedly depending on the degree of tear, and explaining this difference to the patient reduces unnecessary anxiety: perineal pain and swelling are common for the first 7-10 days and then resolve; Second-degree lacerations and episiotomies typically heal in the third postpartum week, and third- and fourth-degree lacerations heal in four to six weeks (UpToDate, postpartum perineal care).
| Injury | Monitoring |
|---|---|
| First-second degree laceration or episiotomy | One contact (face-to-face or virtual) within the first three weeks; recovery, pain and urinary/fecal incontinence are questioned |
| Third-fourth degree laceration (OASIS) | Outpatient clinic examination 1-2 weeks after discharge, then every 1-2 weeks until the repair is completely healed. Those at risk of poor wound healing (diabetes, immunosuppression, smoking), those with extensive repairs, and those who have difficulty maintaining perineal care benefit from weekly monitoring. |
Hygiene and comfort. Unscented pads are changed frequently; Tampons and menstrual cups are avoided for at least six weeks. Cold application is applied to the perineum for 24 hours, then proceed to warm water baths; A meta-analysis reported that cold application was most effective on the second postpartum day (Kurnaz 2025, Int J Nurs Stud). The splash bottle reduces external dysuria and burning by flushing the perineum with warm water during urination. Sitz baths are recommended for about five minutes each time, four times a day or after each defecation; The vaginal and rectal area must be completely submerged, including the sutures. Most stitches dissolve spontaneously and this should be clearly explained to the patient (UpToDate, postpartum perineal care). Constipation prevention is especially valuable in sphincter injury (high fiber diet, 2-3 liters of water per day, stool softener and laxative when necessary); However, in a meta-analysis, while laxative use increased the frequency of defecation, it also increased the frequency of diarrhea and fecal incontinence (Turawa 2015, Cochrane). In third-fourth degree lacerations, rectal drug administration is generally avoided.
Wound dehiscence: Dehiscence can occur without infection, though infection often accompanies it; sexual activity should be asked about in dehiscence without signs of infection. The highest risk is in third- and fourth-degree lacerations. In first- and second-degree dehiscence, expectant management (healing by secondary intention) and re-repair yield similar outcomes, and the choice is shared with the patient. Third- and fourth-degree repair dehiscence is typically managed with antibiotics plus operative debridement back to healthy tissue followed by secondary repair; this approach minimizes fistula risk. In a systematic review, childbirth-related perineal wound infection was reported in 0.1–24.0% and wound dehiscence in 0.2–25.0% (UpToDate, postpartum complications, December 2025). Post-cesarean wound infection is diagnosed in 2.5–16% of patients, usually 4–7 days after surgery (UpToDate, postpartum complications, December 2025).
The definition of postpartum fever is an oral temperature ≥38.0°C on any two of the first 10 postpartum days, excluding the first 24 hours. Differential diagnosis: surgical site infection, endometritis (fever + fever-parallel tachycardia + midline lower abdominal pain + uterine tenderness), pelvic abscess, mastitis/breast abscess, urinary infection, septic pelvic thrombophlebitis, C. difficile infection, and drug fever. White blood cell count does not predict infection—leukocytosis up to 15,000/µL is common in postpartum patients, and workup is reserved for clinical suspicion (UpToDate, postpartum physiology, July 2026).
The median pain resolution time after vaginal birth is 7-14 days and after cesarean section it is 12-27 days (UpToDate, postpartum physiology, July 2026). Afterpains occur in half of women in the first 48 hours, are aggravated due to the release of oxytocin during breastfeeding, are more common in multiparous women, and usually disappear by the end of the first week; Severe afterpain after vaginal birth is atypical and requires seeking another source (UpToDate, postpartum physiology, July 2026).
First-line NSAID or acetaminophen; If both alone are insufficient, they can be used together. NSAIDs are the first choice for perineal pain: in a meta-analysis of 28 studies, adequate pain control at four hours was approximately twice as likely with NSAIDs than with placebo and approximately 50% more likely with acetaminophen (Wuytack 2016, Cochrane). The recommended schedule is ibuprofen 600 mg every 6 hours (maximum 2400 mg/day in normal renal function) when necessary during the first postpartum week, and if not sufficient, additional acetaminophen 650 mg every 6 hours (maximum 3250 mg/day) (UpToDate, postpartum perineal care).
Opioid: carries risk of unnecessary and persistent use. Most patients do not require opioids after vaginal delivery, and opioid prescription is associated with persistent future opioid misuse even after adjusting for confounding factors. The risk of an opioid-naïve mother becoming a persistent user after vaginal birth was 0.59% and 1.7% in two studies; It was reported as 0.12%, 0.36%, 0.84% and 2.2% in four studies after cesarean section. Limiting the amount prescribed is recommended—one review reported that patients used approximately 10 tablets after cesarean discharge and that the amount prescribed affects the number of tablets taken (UpToDate, postpartum physiology, July 2026).
Analgesic selection in the breastfeeding woman. Preferred: acetaminophen (considered compatible with breastfeeding by the Academy of Breastfeeding Medicine, first choice) and short half-life NSAIDs (ibuprofen, diclofenac suppository; relative infant dose less than 1%) (ABM Clinical Protocol 15, 2012). Naproxen is avoided due to its long half-life (>6 hours); If the breastfed baby has a duct-dependent cardiac lesion, all NSAIDs are avoided. If opioids are required, oxycodone and hydrocodone do not appear to carry the risks of codeine and tramadol. It is recommended to avoid codeine and tramadol: in ultra-rapid metabolisers due to CYP2D6 variation, the active metabolite is excreted in milk and may lead to excessive infant sedation and, in extreme cases, fatal overdose (variant frequency 4-5% in the US population); The FDA issued a warning for these two drugs in breastfeeding women in 2017 (FDA Drug Safety Communication, 2017). Meperidine is avoided due to dose-dependent neonatal sedation; Aspirin is used with caution if Reye's syndrome is suspected (daily low-dose aspirin is a separate condition). NSAIDs have not been found harmful in hypertensive postpartum patients; ACOG recommends that they be considered first line in all individuals, including hypertensives (ACOG Clinical Consensus 1, 2021).
Mental health conditions, including suicide, homicide, and substance use disorder, are among the leading causes of maternal mortality in the United States (UpToDate, postpartum physiology, July 2026). ACOG, American Academy of Pediatrics, and USPSTF recommend that all women be screened for postpartum depression and anxiety; screening is appropriate with or without a previous history of depression (ACOG Clinical Practice Guideline 4, 2023).
| Area | Vehicle | Note |
|---|---|---|
| Depression | Edinburgh Postnatal Depression Scale (EPDS) — most commonly used validated scale; alternative PHQ-9 | Screening + adequate support improves clinical outcome; treatment (especially cognitive behavioral therapy) is associated with symptom remission (USPSTF 2016, JAMA) |
| Anxiety | PHQ-4 (screens for both anxiety and depression); GAD-7 for anxiety severity | Screening has no direct evidence on outcome; however, psychological interventions provide moderate benefit for anxiety symptoms (USPSTF 2023, JAMA) |
| Bipolar disorder | Validated bipolar screening tool | Screen for depression BEFORE starting pharmacotherapy — misdiagnosis may lead to mania, mixed state, rapid cycling, or psychosis (associated with self-harm and infanticide) (ACOG Clinical Practice Guideline 4, 2023) |
| PTSD | Primary care screening tool adapted to postpartum: "What was your birth experience like? Do you wish things had gone differently? Have you had any distressing thoughts since birth?" | High risk groups: complicated pregnancy/birth, negative emotional birth experience, history of trauma |
| Substance use | Universal screening with standard screening tool (nicotine, alcohol, illicit substance, prescription drug abuse) | Evaluative interview for those who screen positive, referral to treatment if necessary |
| Intimate partner/domestic violence | Validated scan tools | At the first antenatal visit, at least once each trimester, and again at postpartum care |
In cases of suspected postpartum psychosis, urgent psychiatric hospitalization is usually indicated; psychosis has been associated with infanticide and suicide, and continuous bedside observation may be used to keep the patient safe until transfer occurs (ACOG Clinical Practice Guideline 4, 2023).
Healthcare provider, peer, and/or lactation consultant support increases postdischarge breastfeeding rates; Addressing breastfeeding difficulties at the postpartum visit was associated with maintenance of breastfeeding at the fourth month (UpToDate, postpartum physiology, July 2026). Primary engorgement is due to interstitial edema and the onset of abundant milk production; it typically begins at 24–72 hours (range 1–7 days), and symptoms peak on average on days 3–5. Engorgement can cause a short-term mild fever; However, every fever requires investigation of the source of infection. Supportive care is sufficient within a few days: warm compress before breastfeeding, cold compress between feedings, softening with reverse pressure before latching, mild analgesic—vigorous breast massage is avoided due to the risk of tissue damage and infection (UpToDate, postpartum physiology, July 2026).
In women who are not breastfeeding, tight bras and avoidance of breast stimulation suppress lactation by 60-70% and are the recommended treatment. Medication is not recommended for lactation suppression—the risk of existing medications exceeds the expected benefit for self-limiting symptoms; Bromocriptine was abandoned due to postpartum hypertension, seizures, and stroke. In the patient requesting lactation inhibition after fetal death/stillbirth, a single dose of 1 mg cabergoline orally can be administered, ideally within the first 24 hours, after discussing the risks (UpToDate, postpartum physiology, July 2026); Hypertension is a contraindication.
The incidence of mastitis can be reduced by improving breastfeeding technique by frequent and complete emptying of the breast. Lactation mastitis typically presents with a hard, red, tender area on one breast and a fever exceeding 38.5°C; A tender and fluctuating area suggests an abscess. Mastitis that does not respond quickly to adequate drainage and antibiotics should be investigated for resistant factors such as abscess or MRSA (UpToDate, postpartum complications, December 2025).
This is the most easily missed but most valuable component of the postpartum visit in the long term. Women with a history of gestational diabetes, pregnancy-associated hypertension, or preterm birth—even if postpartum blood pressure and glucose tolerance testing are normal—are at increased risk for future cardiovascular disease; The same is true for placenta-mediated disorders (fetal growth restriction, preeclampsia, abruption). ACOG recommends that these women be informed of the increased risk and that this information be recorded in the health record; In the case of a history of preeclampsia, this may include annual assessment of blood pressure, lipid, fasting blood glucose and body mass index (ACOG CO 736, 2018; Lewey 2024, Circulation).
Postpartum OGTT — reconsider timing: Women with gestational diabetes should undergo a postpartum oral glucose tolerance test and be informed about their risk of future diabetes — even if the test is normal. The traditional timing is 4–12 weeks postpartum; however, this is impractical for a woman who has just given birth, and testing is often not done at all. Increasing evidence shows that testing on the second postpartum day while hospitalized is reliable and increases compliance to close to 100% (UpToDate, postpartum physiology, July 2026). If the patient is discharged without testing, mail, telephone, and/or electronic reminders will increase compliance.
Future risk may be reduced when nutrition, exercise, body mass index within the normal range, sleep health, and smoking cessation are discussed at this visit. Interpregnancy spacing should also be discussed: both short (<6 months) and long (>60 months) intervals are associated with an increased risk of adverse outcomes, with the optimum interval being approximately 18-24 months — although extending the interval may not be the best option for women over 35 or with a strong family history of early menopause (ACOG CO 736, 2018).
There is no evidence-based guideline for when sexual activity can begin. The reasonable framework is that vaginal intercourse can be safely resumed when the perineum has healed, the woman is emotionally ready, and contraception is used if desired. Some women may feel ready as early as two weeks; many wait at least six to eight weeks due to fatigue, decreased sexual desire, pain, vaginal dryness or lochia, cultural practices, or postpartum sadness/depression (UpToDate, postpartum physiology, July 2026).
Fears frequently expressed by patients should be addressed in a targeted manner: fear that the stitches will be removed, fear that defecation will damage the repair, and fear that the introitus will become permanently narrow or the vagina will remain too wide. It can be said that sexual function can be returned in approximately six to eight weeks after perineal repair; A woman who cannot return to prenatal sexual activity within three months should be evaluated, and this evaluation includes physical, emotional and relational dimensions together. Dyspareunia and vaginal dryness are common, especially in breastfeeding women, due to the hypoestrogenic state and can be managed with regular vaginal moisturizing and the use of additional lubricant for intercourse (UpToDate, postpartum perineal care).
The postpartum period is an ideal time to access contraception: the patient is known to be not pregnant, is highly motivated, and is under the care of a clinician with appropriate expertise. On the other hand, in international data, the unmet need for contraception in the first year following birth rises to 62% (UpToDate, postpartum contraception, January 2025). Contraceptive plans should be discussed again in the third trimester and before the patient leaves the hospital; Since ovulation can return as early as the 25th day in a woman who is not fully breastfeeding, contraception is started in the third postpartum week at the latest (UpToDate, postpartum contraception, January 2025).
The institutions are close but not identical here: WHO recommends an interval of at least 24 months; ACOG recommends counseling to avoid intervals shorter than 6 months and to discuss the risks and benefits of re-pregnancy before 18 months. Data from high-resource settings show that the relationship is weaker at intervals exceeding 6 months (WHO MEC, 2015; ACOG CO 736, 2018).
LAM is the conscious use of breastfeeding as a contraceptive for up to six months after birth, provided that the patient is amenorrheic and does not use supplements or a breast pump. Six-month life table pregnancy rates range from 0.45% to 7.5% (Van der Wijden 2015, Cochrane). The risk of pregnancy in the first six months for a woman meeting all of these criteria is <5% in most populations and increases thereafter (Van der Wijden 2015, Cochrane).
The practical weakness of LAM: 20-56% of fully breastfeeding women are not amenorrheic by the sixth month, and many stop full breastfeeding before the sixth month. There is also no evidence that LAM delays the return of menstruation any further than women who exclusively breastfeed and are amenorrheic but do not report using any method. Given the variability of visit attendance, it is more prudent to use the first months to support full breastfeeding while also providing a high-impact method in the first few weeks if desired (Van der Wijden 2015, Cochrane).
There are two separate reasons that determine timing and they should not be confused. First, the risk of VTE: due to the curve given above, estrogen-containing methods are restricted in the early postpartum period — combined hormonal contraceptive (CHC) use in healthy non-pregnant women increases the risk of VTE by 3-7 times compared to non-users (UpToDate, postpartum contraception, January 2025). The second is breastfeeding concern: concern that the hormone may affect lactogenesis. Because WHO and CDC weight these two justifications differently, their recommendations differ.
| Method | CDC US MEC 2024 | WHO eligibility criteria (2015) |
|---|---|---|
| Progestin-only implant (etonogestrel, LNG) | Can be used any time after birth (<21 days category 1) | Same direction — supports immediate use |
| Progestin-only pill (POP) | Any time after birth (<21 days category 1) | Can be used before 6 weeks; no restrictions after |
| Progestin-only injection (DMPA) | Can be used including immediately after birth; No restrictions after 42 days | Recommends delaying breastfeeding until week 6 (theoretical concern based on animal data); Supports use in environments where no other method is accessible |
| IUD (copper and LNG) | <10 minutes and 10 minutes to 4 weeks after placental delivery category 2; ≥4 weeks category 1 | states that the risks outweigh the benefits for the LNG-IUD due to the lack of expulsion data between 48 hours and 4 weeks (this limitation is related to expulsion, not breastfeeding) |
| Combined hormonal (pill, patch, ring) — breastfeeding | <21 days category 4 (not used) 21-30 days category 3 30-42 days: category 2 if there are no additional VTE risk factors, category 3 if present · >42 days category 2 | Recommends postponing use until 6 months postpartum in primarily breastfeeding women; in the meantime, a progestin-only or non-hormonal method is recommended |
| Combined hormonal — non-breastfeeding | <21 days category 4 · 21-42 days: category 2 if there are no additional VTE risk factors, category 3 if present · >42 days category 1 | — |
What does the category mean: In US MEC and WHO criteria 1 = no restrictions · 2 = benefits generally exceed theoretical/proven risks · 3 = risks generally exceed benefits (careful clinical evaluation and monitoring required if used) · 4 = unacceptable health risk, method not to be used. The 2024 US MEC supersedes the 2016 version, and recommendations on breastfeeding/postpartum have been revised in this version (Nguyen 2024, MMWR Recomm Rep).
The evidence base explains this divergence: overall the available evidence does not support a significant and consistent effect of hormonal contraception on breastfeeding outcomes, and the amount of estrogen and progestin excreted in milk to the infant is very small. Studies with progestin-only methods either showed no difference or improved breastfeeding outcomes; CHC studies are inconsistent. However, high-quality data is limited and WHO's more cautious stance stems from the weight of breastfeeding for infant health in low-resource settings (WHO MEC, 2015).
An IUD can be placed at three distinct times after delivery: postplacental (within 10 minutes of placental delivery), early postpartum (typically weeks 2-4), and late/interval (usually week 6 or later). All three timings are safe—rates of perforation, infection, and heavy vaginal bleeding are very low. The key difference lies in expulsion rates.
| Comparison | Finding |
|---|---|
| General range by timing | 2-40% for immediate and early placement; 0-4% at 6 weeks and later; 3-10% in non-postpartum patients |
| Immediate/early vs interval (48 studies, 7661 placements) | Eight-fold increase in risk of expulsion (adjusted RR 8.33; 95% CI 4.32-16.08) (Averbach 2020, AJOG) |
| Five-year cumulative expulsion (>320,000 patients) | Highest: 10.73% (95% CI 9.12–12.61) with insertion on days 0–3; lowest: 3.18% (95% CI 2.95–3.42) with insertion at 6–14 weeks (Armstrong 2022, JAMA Netw Open) |
| Vaginal vs cesarean (immediate insertion) | Vaginal birth increases the risk of expulsion fourfold (adjusted RR 4.57; 95% CI 3.49-5.99) (Averbach 2020, AJOG) |
| LNG vs copper IUD (<4 weeks) | Risk approximately doubles with an LNG-IUD (adjusted RR 1.91; 95% CI 1.50–2.43) (Averbach 2020, AJOG). |
| 2-4. week vs 6-8. week (randomized) | No increased risk of complete expulsion (between-group difference 2.0%; 95% CI −0.5 – 5.7; predefined noninferiority limit 6% (Averbach 2023, JAMA)) |
Paradox — and its solution: The odds of using an IUD six months after birth are twice as high in those with postplacental insertion as with interval insertion (OR 2.04; 95% CI 1.01-4.09), although the risks of expulsion, perforation and malposition are higher, and in the decision analysis, intended postplacental insertion is more effective than intended late insertion in preventing pregnancy at one year. The only variable that determines this difference is the rate at which patients return to postpartum visits: for late placement to be more effective, the clinic's follow-up rate must be 90% or above. Public health benefit may conflict with individual benefit; The risks and benefits of both timings should be clearly explained to the patient (Sonalkar 2018, Obstet Gynecol).
Practical details: Postplacental placement is contraindicated in the presence of chorioamnionitis, endometritis or active postpartum bleeding. In approximately one-quarter of IUDs placed postplacental after vaginal delivery, the strings fold into the uterus and cannot be seen on speculum examination; a string check is a poor test for assessing IUD position (sensitivity 36.2%, specificity 84.5%) (UpToDate, postpartum contraception, January 2025). For this reason, ultrasound at 4-6 weeks is recommended for patients who choose a postplacental IUD. While the malposition rate was 15% in six months for immediate placement, it was 5.4% for early (2-4 weeks) placement and 0% for interval placement (Averbach 2023, JAMA).
The progestin-only implant can be placed safely at any time after birth and can be offered before discharge to ensure access to the method. DMPA can be administered during the labor admission; Since it is effective for 12 weeks with a single injection, it serves as a bridge to an outpatient clinic visit. A link between DMPA and postpartum depression is neither proven nor excluded; Since the data are contradictory, DMPA should not be restricted in the patient who wishes to do so, but depression screening should be performed regardless of the method chosen. Progestin-only pills can be started at any time; norethindrone 0.35 mg should be taken at approximately the same time each day, while the newer drospirenone 4 mg (24 active + 4 placebo) reliably suppresses ovulation even in the event of a missed pill (UpToDate, postpartum contraception, January 2025).
Permanent contraception can be applied after vaginal birth by infraumbilical mini-laparotomy—preferably within 24-48 hours, no later than six days—as partial salpingectomy or during cesarean section; There is the option of bilateral total salpingectomy to reduce the risk of high-grade serous ovarian cancer during cesarean section. The critical issue is access: one-third to one-half of patients seeking permanent postpartum contraception do not receive the procedure they want (risk factors: high body mass index, time of birth, vaginal delivery rather than cesarean section), and the consequence of this delay is severe—up to 47% of unintended pregnancies have been reported in the first postpartum year (Thurman and Janecek 2010, Obstet Gynecol). If the procedure cannot be performed during the maternity hospitalization, another highly effective method should be offered and an appointment should be made for the interval laparoscopic procedure.
Counseling should begin in the antenatal period. Consent in permanent contraception should be considered as a process consisting of the stages of providing information + verifying voluntariness + verifying understanding. If necessary, an interpreter should be used and the patient's decision should be reconfirmed before surgery. For the male partner, vasectomy is also a highly effective (<1% failure), minimally invasive, and widely accessible option (UpToDate, postpartum contraception, January 2025).
All patients should be informed about emergency contraception: copper IUD, LNG 52 mg IUD, oral LNG and oral ulipristal acetate are safe in postpartum and breastfeeding patients. The only caveat is that breastfeeding is not recommended for 24 hours after taking ulipristal acetate — milk is expressed and excreted during this time. Ethinyl estradiol + LNG (Yuzpe method) is avoided in the first three to six weeks due to the risk of VTE. Pericoital methods (diaphragm, cervical cap) are not used for the first six weeks because the uterus is still involution; condoms and spermicides can be used without restrictions (US MEC, 2024).
Last updated: . Guide numbers and publication years have been verified against current catalogues.